(thirdQuint)CD19-CAR-T Cells in Patients With R/R B-ALL.

 Primary objective: To investigate the safety and efficacy of autologous or HLA-haploidentical Allo-CD19-CAR-T cells in the treatment of patients with relapsed or refractory acute B-cell lymphoblastic leukemia.

 Secondary objective: To Assess the patient's quality of life after receiving the treatment.

.

 CD19-CAR-T Cells in Patients With R/R B-ALL@highlight

This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells") in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).

